Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care
Metabolites · 16.11.2026 · 16 (11) · 894
DOI: 10.3390/metabo16110894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 16.11.2026. Verfasst von Najwa F. Mourad und 3 weiteren Autor:innen. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: As survival among people living with HIV (PLWH) improves, metabolic and age-related comorbidities have become increasingly important. This narrative review evaluates the evolving role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in HIV care, distinguishing established benefits from emerging evidence across metabolic, hepatic, cardiovascular, inflammatory, immune, neurocognitive, ageing, and body-composition outcomes.
Methods
PubMed was searched for English-language publications from January 2016 to July 2026. Randomised trials, interventional and observational studies, case reports, reviews, and meta-analyses were considered. Two authors independently extracted study characteristics and outcomes. Studies were grouped by parent trial or cohort and synthesised narratively without statistical pooling.
Results
GLP-1 RAs, particularly semaglutide, show reduced body weight and visceral adiposity and improved glycaemic control in PLWH, although the range of weight loss varied across studies. Benefits were also observed for liver fat; triglycerides; very-low-density lipoprotein and remnant lipoproteins; and selected inflammatory markers, particularly high-sensitivity C-reactive protein. Evidence for immune effects, neurocognitive improvement, biological ageing, and preservation of muscle mass and function remains limited or inconsistent. Treatment was generally well tolerated, with gastrointestinal symptoms most frequently reported. Clinically significant interactions with contemporary antiretroviral therapy have not been identified, although dedicated interaction studies remain limited.
Conclusions
GLP-1 RAs may have a role in HIV care extending beyond weight reduction and glucose control. Larger, independent, longer-term studies are needed to clarify broader clinical benefits, mechanisms, long-term safety, and interactions with antiretroviral therapy.
Zitieren
APA
Mourad, N. F., Hammoud, R., Tsioutis, C., & Alon-Ellenbogen, D. (2026). Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care. Metabolites, 16(11), 894. https://doi.org/10.3390/metabo16110894
Vancouver
Mourad NF, Hammoud R, Tsioutis C, Alon-Ellenbogen D. Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care. Metabolites. 2026;16(11):894. doi:10.3390/metabo16110894
BibTeX
@article{Mourad2026,
author = {Mourad, Najwa F. and Hammoud, Rami and Tsioutis, Constantinos and Alon-Ellenbogen, Danny},
title = {Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {11},
pages = {894},
doi = {10.3390/metabo16110894}
}
EUVIMED